1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Carcinomas – Pipeline Review, H1 2013

Carcinomas – Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 139 pages

Carcinomas – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Carcinomas - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Carcinomas. Carcinomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Carcinomas.
- A review of the Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Carcinomas pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Carcinomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Carcinomas pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Carcinomas - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Carcinomas Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Carcinomas 11
Carcinomas Therapeutics under Development by Companies 13
Carcinomas Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Carcinomas Therapeutics - Products under Development by Companies 20
Carcinomas Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Carcinomas Therapeutics Development 22
Sequella, Inc. 22
Eli Lilly and Company 23
GlaxoSmithKline plc 24
Merck and Co., Inc. 25
Takara Holdings Inc. 26
Aduro BioTech 27
Bayer AG 28
Momenta Pharmaceuticals, Inc. 29
PCI Biotech AS 30
Nanobiotix 31
Cancer Research Technology Limited 32
Spectrum Pharmaceuticals, Inc. 33
Telormedix SA 34
Cellceutix Corporation 35
Viventia Biotechnologies Inc. 36
Lytix Biopharma AS 37
Carcinomas - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 45
cetuximab - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
cixutumumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
ridaforolimus - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
(amphinex + bleomycin sulfate) - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
M-402 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
ramucirumab - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
ramucirumab - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
SQ-109 - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
SPI-1620 - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
imiquimod - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
oportuzumab monatox - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
Kevetrin - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
HF-10 - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
NPI-1342 - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
MOC31-PE - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
LTX-315 - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
aspirin - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
nelfinavir mesylate - Drug Profile 85
Product Description 85
Mechanism of Action 85
RandD Progress 85
GV-1001 + LTX-315 - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
bevacizumab + [cisplatin] + Radiation Therapy - Drug Profile 87
Product Description 87
Mechanism of Action 87
RandD Progress 87
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
bevacizumab + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 89
Product Description 89
Mechanism of Action 89
RandD Progress 89
lambrolizumab - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
cidofovir - Drug Profile 91
Product Description 91
Mechanism of Action 91
RandD Progress 91
BAY-94-9343 - Drug Profile 92
Product Description 92
Mechanism of Action 92
RandD Progress 92
ANZ-100 - Drug Profile 94
Product Description 94
Mechanism of Action 94
RandD Progress 94
LY-2510924 - Drug Profile 95
Product Description 95
Mechanism of Action 95
RandD Progress 95
dasatinib + [erlotinib hydrochloride] + [gemcitabine hydrochloride] - Drug Profile 96
Product Description 96
Mechanism of Action 96
RandD Progress 96
interleukin-15 - Drug Profile 97
Product Description 97
Mechanism of Action 97
RandD Progress 97
interferon alfa-2b biosimilar - Drug Profile 99
Product Description 99
Mechanism of Action 99
RandD Progress 99
Anti-S100A4 Monoclonal Antibody - Drug Profile 100
Product Description 100
Mechanism of Action 100
RandD Progress 100
NBTX-IV - Drug Profile 101
Product Description 101
Mechanism of Action 101
RandD Progress 101
Platinum Based Compounds - Drug Profile 102
Product Description 102
Mechanism of Action 102
RandD Progress 102
PMA-104R - Drug Profile 103
Product Description 103
Mechanism of Action 103
RandD Progress 103
Carcinomas Therapeutics - Drug Profile Updates 104
Carcinomas Therapeutics - Discontinued Products 126
Carcinomas Therapeutics - Dormant Products 127
Carcinomas - Product Development Milestones 130
Featured News and Press Releases 130
May 01, 2013: GSK Announces FDA Extension Of PDUFA Date For Trametinib By Three Months 130
Jun 29, 2012: Topotarget Announces Top-Line Results From Phase II Trial Of Belinostat For Treatment Of Cancer 130
Oct 04, 2011: Fresenius Biotech Obtains Reimbursement Approval For Removab Antibody In Belgium 131
Sep 19, 2011: Spectrum Announces Positive First Part Of Phase I Study Results Of SPI-1620 In Carcinomas 131
Jun 14, 2011: ImmunoGen Earns Milestone With BAY 94-9343 IND Submission 132
Jun 07, 2011: Fresenius Biotech Presents New Data Of Trifunctional Antibody Removab At ASCO 133
Jun 07, 2011: Fresenius Biotech Presents New Data Of Trifunctional Antibody Removab At ASCO 134
May 26, 2011: ImmunoGen Announces Clinical Presentation Of IMGN901 At ASCO 2011 Annual Meeting 135
Apr 04, 2011: ImmunoGen Announces First Data For New Therapeutic For Ovarian Cancer And Other Carcinomas 135
Apr 04, 2011: Curis Announces Investigator-Initiated Phase II Study Results Presented At 102nd AACR Annual Meeting 2011 136
Appendix 138
Methodology 138
Coverage 138
Secondary Research 138
Primary Research 138
Expert Panel Validation 138
Contact Us 139
Disclaimer 139

List of Tables

Number of Products Under Development for Carcinomas, H1 2013 11
Products under Development for Carcinomas - Comparative Analysis, H1 2013 12
Number of Products under Development by Companies, H1 2013 14
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Investigation by Universities/Institutes, H1 2013 21
Sequella, Inc., H1 2013 22
Eli Lilly and Company, H1 2013 23
Merck and Co., Inc., H1 2013 25
Takara Holdings Inc., H1 2013 26
Aduro BioTech, H1 2013 27
Bayer AG, H1 2013 28
Momenta Pharmaceuticals, Inc., H1 2013 29
PCI Biotech AS, H1 2013 30
Nanobiotix, H1 2013 31
Cancer Research Technology Limited, H1 2013 32
Spectrum Pharmaceuticals, Inc., H1 2013 33
Telormedix SA, H1 2013 34
Cellceutix Corporation, H1 2013 35
Viventia Biotechnologies Inc., H1 2013 36
Lytix Biopharma AS, H1 2013 37
Assessment by Monotherapy Products, H1 2013 38
Assessment by Combination Products, H1 2013 39
Assessment by Stage and Route of Administration, H1 2013 41
Assessment by Stage and Molecule Type, H1 2013 44
Carcinomas Therapeutics - Drug Profile Updates 104
Carcinomas Therapeutics - Discontinued Products 126
Carcinomas Therapeutics - Dormant Products 127
Carcinomas Therapeutics - Dormant Products (Contd..1) 128
Carcinomas Therapeutics - Dormant Products (Contd..2) 129

List of Figures

Number of Products under Development for Carcinomas, H1 2013 11
Products under Development for Carcinomas - Comparative Analysis, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Discovery and Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 38
Assessment by Combination Products, H1 2013 39
Assessment by Route of Administration, H1 2013 40
Assessment by Stage and Route of Administration, H1 2013 41
Assessment by Molecule Type, H1 2013 42
Assessment by Stage and Molecule Type, H1 2013 43

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.